Current Issue
Volume: 37
Number: 4
Index: December 2021
Clinical Focus: THE INJURED ATHLETE
Editorial Calendar
April 2010
Clinical Focus: Hypertension
  • Hypertension in athletes
    • Antihypertension medication and its effects on athletes
  • Risk of CVD in professional athletes
  • NSAIDs in sports medicine
  • Arterial and venous injuries in athletes
  • Family history and exercise-induced cardiac remodeling (eg, left ventricular hypertrophy)
  • Physical activity for non-athletes with hypertension
    • Exercise programs for patients with hypertension
  • Sleep changes related to hypertension
  • Resuming exercise after rhabdomyolysis
  • Gender differences in hypertension and treatment options
  • Dietary approaches to prevention and treatment hypertension
  • Exercise and the vascular wall
  • Effects of exercise on aging
  • Association between exercise and atherosclerosis
  • Sodium ingestion and hypertension
  • Arrhythmia and "holiday heart"
  • Increased arterial stiffness in children, patients with type 2 diabetes
  • COPD
View More
Submission deadline: March 05
Fast-Track deadline: March 15
Fast-Track
About
Fast-Track peer review is available for those papers requiring immediate review (for an additional fee). Complete peer review is finalized in 1-2 weeks and comments are provided to the author within 72 hours of their receipt by the editorial office. Authors are asked to submit a revised manuscript within 10-12 days. Accepted manuscripts are processed within 2-3 weeks, published online within 3 business days of final author approval, and in print in the next available issue.
Submissions
Submit your FAST-TRACK manuscript online today. It's fast, it's easy! Just follow the detailed instructions, fill in all the required fields, and upload your manuscript.
Get started NOW!
Contacts
Libraries:
[email protected]

Reprints:
[email protected]

Subscriptions:
[email protected]

Supplements:
[email protected]

Document Delivery Services
120216-2010:

[email protected]

Editorial:
[email protected] [email protected]

Website:
[email protected]

Managing Director:
John Elduff
Phone: 610-889-3733
Fax: 1-866-297-3168
[email protected]

General Information
Phone: 610-889-3733
Fax: 1-866-297-3168
1235 Westlakes Drive
Suite 320
Berwyn, PA 19312
doi: 10.3810/psm.2021.12.18
The Physician and Sportsmedicine: Volume 36: No.1
The H-Wave® Device Induces NODependent Augmented Microcirculation and Angiogenesis, Providing Both Analgesia and Tissue Healing in Sports Injuries
Kenneth Blum, PhD; Chi-Kung Ho, MD; Amanda L.C. Chen, PhD; Michael Fulton, MD; Brent Fulton, MD; Wayne L. Westcott, PhD, CSCS; Gary Reinl; Eric R. Braverman, MD; Nicholas DiNubile, MD; and Thomas J.H. Chen,PhD
Abstract: The hypothesis that the H-Wave® device (Electronic Waveform Lab, Inc., Huntington Beach, CA), a small-diameter fiber stimulator, is a paradigm shift of electrotherapeutic treatment of pain associated with human neuropathies and sports injuries is based on a number of its properties. The primary effect of H-Wave® device stimulation (HWDS) is the stimulation of "red-slow-twitch" skeletal muscle fibers. The authors propose, based on the unique waveform, that the H-Wave® device specifically and directly stimulates the small smooth muscle fibers within the lymphatic vessels ultimately leading to fluid shifts and reduced edema. In unpublished rat studies, it has been observed that HWDS induces protein clearance. The H-Wave® device was designed to stimulate an ultra low frequency (1-2 Hz), low tension, nontetanizing, and nonfatiguing contraction, which closely mimics voluntary or natural muscle contractions. The H-Wave® device can stimulate small fibers due in part to its exponentially decaying waveform and constant current generator activity. The main advantage of these technologies over currently applied electrical stimulators (eg, transcutaneous electrical nerve stimulator [TENS], interferential [IF], neuromuscular electrical stimulation [NMES], high-volt galvanic, etc.) is that H-Wave\'s® small fiber contraction does not trigger an activation of the motor nerves of the large white muscle fibers or the sensory delta and C pain nerve fibers, thus eliminating the negative and painful effects of tetanizing fatigue, which reduces transcapillary fluid shifts. Another function of the H-Wave® device is an anesthetic effect on pain conditions, unlike a TENS unit which in the short term activates a hypersensory overload effect (gate theory) to stop pain signals from reaching the thalamic region of the brain. When the H-Wave® device is used at high frequency (60 Hz), it acts intrinsically on the nerve to deactivate the sodium pump within the nerve fiber, leading to a long-lasting anesthetic/analgesic effect due to an accumulative postsynaptic depression. Moreover, HWDS produces a nitric oxide (NO)-dependent enhancement of microcirculation and angiogenesis in rats. Thus, the authors hypothesize that because of these innate properties of the H-Wave® device, it may provide a paradigm shift for the treatment of both short- and long-term inflammatory conditions associated with pain due to sports injuries. A recent meta-analysis found a moderate-to-strong effect of the H-Wave® device in providing pain relief, reducing the requirement for pain medication, and increasing functionality. The most robust effect was observed for improved functionality, suggesting that the H-Wave® device may facilitate a quicker return to the field.

Keywords: H-Wave® device; sportsmedicine, nitric oxide-dependent blood flow; analgesia; angiogenesis
(read)